Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (4881)	11/5/1997 2:50:00 AM
From: John Metcalf	Respond to of 9262

AKRN -- made new annual high. Fundamental story is new product competing against Merck's Timoptic, the world's largest selling opthalmic. Charges for consolidation (from Louisiana to Illinois) are past. Finances are secured with line of credit and profitability. New product (Piroxicam, from Pfizer) is in Phase III trials. DEPO -- Depocyt, their first product, is confirmed on the FDA's Oncologic Drug Advisory Committee's calendar for December 18-19. As this is a safer and more effective version of cytarabine, approval is likely. Depo-morphine and depo-amikacine are following in human trials.

To: Galirayo who wrote (4881)	11/5/1997 11:27:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9262

[ sto bio, 11/4 ] Ray: OK, we'll drop MCDE and add NTII. NTII is in danger of being delisted, however. Needs cash. This minicap has a new, high-powered CEO. With two products in clinical testing that address large markets, this creature is, IMO, either going to slowly rot away into tax selling or soar on news from a recently completed phase II clinical trial (memantine) in peripheral neuropathy. A prediction from me, at this time, would only be a guess. I was not clear on the "messages" you were sending regarding CGEN and NSTA, so I left them off of the list. So, the list now looks like this........ DEPO AKRN CTII CVAS NTII Respected biotechs from 11/4 list....... BIPL (hospital-based reagents) MAGN (I'm neutral, chronic underperformer) MATK (hits list again, business plan in turmoil, products from algae) NZYM (doesn't seem like a place to focus, to me) PBIO (doesn't count, being purchased) XOMA (too risky for me, given current circumstances) Rebecca..... yup, I missed ARDM. Again, I am not going to field questions about given companies. I really, really don't want to be perceived as rude. However, I want to keep the focus on Ray's procedures and how they intersect my view of companies that will thrive long-term. While I don't want to field questions, I do feel that it would be really cool if you, Carol, John or others chose to bounce your selected lists off of Ray and add to THE LIST as you see fit. Rick